NCT01159327View on ClinicalTrials.gov

Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

April 30, 2013

Study Completion Date

June 30, 2013

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Sorafenib

Sorafenib 400mg, bid(800mg/day), daily, PO

Trial Locations (1)

Unknown

National Cancer Center, Korea, Goyang-si

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

National Cancer Center, Korea

OTHER_GOV